When the FDA advised vaccine-makers in late June to engineer their boosters to target subvariants BA.4 and BA.5, at the time the “sister variants” accounted for a slight majority of infections. Four months later, new mutations, including BQ.1 and BQ.1.1, are working to surpass the subvariants the omicron boosters targeted.
Read the full post on Becker's Hospital Review - Healthcare News
